 |
Jerusalem, Israel, December 23, 2008
Teva Announces Tentative Approval of Generic Seroquel® Tablets
|
|
Jerusalem, Israel,, December 23, 2008
Teva Completes Acquisition of Barr
|
|
Jerusalem, Israel and Montvale, NJ, December 19, 2008
U.S. Federal Trade Commission Clears Teva's Acquisition of Barr
|
|
Jerusalem, Israel and Montvale, NJ, December 19, 2008
Teva and Barr Receive European Commission Approval for Acquisition
|
|
Jerusalem, Israel, December 9, 2008
Teva Receives Positive Results on AOK Tender
|
|
Jerusalem, Israel, December 8, 2008
Teva Draws on $1.75 Billion Bridge Financing in Connection with Pending Barr Acquisition
|
|
Jerusalem, Israel, November 25, 2008
Teva Announces Agreement on Generic Pulmicort Respules® Patent Challenge
|
|
Jerusalem, Israel, November 20, 2008
Teva Provides Update on Generic Pulmicort Repulses® Launch
|
|
Jerusalem, Israel, November 19, 2008
Teva Receives First U.S. Approval for Generic Pulmicort Respules®; Commences Commercial Launch
|
|
Jerusalem, Israel, November 19, 2008
Teva Announces Agreement on Allegra® Patent Challenge
|
|
Jerusalem, Israel and Lund, Sweden, November 18, 2008
Teva Completes Enrollment in Laquinimod Phase III Clinical Trial
|
|
Jerusalem, Israel, November 13, 2008
Teva to Present at the 2008 Credit Suisse Annual Healthcare Conference
|
|
Jerusalem, Israel, November 9, 2008
Teva Provides Update on Generic Prevacid® Litigation
|
|
Jerusalem, Israel, November 6, 2008
Teva Updates 2008 Financial Outlook
|
|
Jerusalem, Israel, November 6, 2008
Teva Reports Third Quarter 2008 Results
|
|
Jerusalem, Israel, November 3, 2008
Azilect® Shown To Be A Selective Mao-B Inhibitor
|
|
Jerusalem, Israel and Montvale, NJ, October 27, 2008
Teva and Barr Provide Update on Acquisition
|
|
Jerusalem, Israel, October 27, 2008
Teva Announces Settlement Agreement regarding Auction Rate Securities
|
|
Jerusalem, Israel, October 22, 2008
Teva to Report Third Quarter 2008 Financial Results on November 6, 2008
|
|
Jerusalem, Israel, October 20, 2008
Teva Announces FDA Approval and Commercial Launch of Fentanyl Transdermal System
|
|
Jerusalem, Israel, October 16, 2008
Teva announces Sale of its Israeli Veterinary Business to Phibro Animal Health
|
|
Jerusalem, Israel, and Tokyo, Japan, September 24, 2008
Teva and Kowa Announce Strategic Partnership to Create a Leading Generic Pharmaceutical Company in Japan
|
|
Jerusalem, Israel,, September 24, 2008
Teva's Proair® HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication
|
|
Jerusalem, Israel, September 23, 2008
Teva to Present at the UBS Global Life Sciences Conference
|
|
Jerusalem, Israel, September 22, 2008
Teva Introduces Nicardipine HCL Injection in The United States;
First Alternative to Cardene® I.V.
|
|
Jerusalem, Israel, September 19, 2008
Copaxone® Demonstrated Protective Effect in Patients with Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
|
|
Jerusalem, Israel and Lund, Sweden, September 18, 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
|
|
Jerusalem, Israel, September 18, 2008
Longest Prospective Study in MS Confirmed
Robust Clinical Benefits and Safety of Copaxone®
|
|
Jerusalem, Israel, September 16, 2008
Teva Receives EU Marketing Authorization for TevaGrastim®
|
|
Jerusalem, Israel, September 15, 2008
Teva to Present New Treatment Data at World Congress for Multiple Sclerosis
|
|
Jerusalem, Israel, September 14, 2008
Teva Announces Appellate Court Reverses Generic Risperdal® Exclusivity Decision
|
|
Jerusalem, Israel and Montvale, NJ, September 3, 2008
Teva and Barr Receive FTC Request for Additional Information
|
|
Jerusalem, Israel, August 26, 2008
ADAGIO Trial Results Show Teva's Azilect® 1 Mg Tablets Slow Progression of Parkinson's Disease
|
|
Jerusalem, Israel, July 29, 2008
Teva Reports Second Quarter 2008 Results
|
|
Jerusalem, Israel, July 23, 2008
Teva Completes Acquisition of Bentley Pharmaceuticals
|
|
Jerusalem, Israel, July 23, 2008
Teva Introduces First Generic Lamictal® Tablets in the United States
|
|
Jerusalem, Israel, and Montvale, New Jersey, July 18, 2008
Teva and Barr Invites Public to Listen to Webcast
|
|
Jerusalem, Israel and Montvale, NJ, July 18, 2008
Teva to Acquire Barr
|
|
Jerusalem, Israel and Lund, Sweden, July 16, 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial Of Oral Laquinimod
|
|
Jerusalem, Israel, July 14, 2008
ADAGIO Phase III Top Line Data to be Presented at 12th Congress of European Federation of Neurological Societies
|
|
Jerusalem, Israel, July 14, 2008
Teva to Report Second Quarter 2008 Financial Results on July 29, 2008
|
|
Jerusalem, Israel, July 11, 2008
Teva Pharmaceutical Industries Ltd. Statement Regarding COPAXONE®
|
|
Jerusalem, Israel, July 11, 2008
Teva Comments on Paragraph IV Filing for COPAXONE®; Intends to File Lawsuit against Generic Filer for Patent Infringement
|
|
Jerusalem, Israel, July 7, 2008
Teva Provides Update on FORTE Trial
|
|
Jerusalem, Israel, June 30, 2008
Teva Receives First U.S. Approval For Generic Risperdal® Tablets; Commences Commercial Launch
|
|
Jerusalem, Israel & Melbourne, Australia, June 30, 2008
Teva & ANP Announce That ATL/TV1102, a Novel Drug for The Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction In Disease Activity
|
|
Jerusalem, Israel, June 24, 2008
Teva to Present at The Piper Jaffray Third Annual Europe
Conference
|
|
Jerusalem, Israel, June 16, 2008
Teva's AZILECT® 1 mg Tablets Meet End Points in ADAGIO Phase III Trial
|
|
Jerusalem, Israel, June 12, 2008
Teva Announces Tentative Approval of Generic Diovan® Tablets
|
|
Jerusalem, Israel, June 11, 2008
Teva to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
|
|
Jerusalem, Israel, May 30, 2008
Teva Announces Launch of Generic Wellbutrin Xl® Tablets,
150 Mg
|
|
Jerusalem, Israel, May 27, 2008
Teva To Present At The UBS Global Specialty and Generic Pharmaceuticals Conference
|
|
Jerusalem, May 21, 2008
Teva Announces Approval Of Generic Sarafem® Pulvules®
|
|
Jerusalem, Israel, May 12, 2008
Teva To Present At The Bank Of America Health Care Conference
|
|
Jerusalem, Israel, May 6, 2008
Teva Reports First Quarter 2008 Results
|
|
Jerusalem, Israel, April 30, 2008
Teva Announces Global In-Market First Quarter Sales
Of Copaxone® Increased 35% To $542 Million
|
|
Jerusalem, Israel, April 28, 2008
Teva Announces Approval Of Generic Flolan® For Injection
|
|
Jerusalem, Israel, April 23, 2008
Teva To Report First Quarter 2008 Financial
|
|
Jerusalem, April 17, 2008
Teva Announces Tentative Approval Of Generic Evista® Tablets
|
|
Jerusalem, April 17, 2008
Teva Announces Tentative Approval Of Generic Maxalt® Tablets
|
|
Jerusalem, April 16, 2008
Early Treatment With Copaxone® Significantly Delayed
Progression To Clinically Definite Multiple Sclerosis
|
|
Jerusalem, Israel, April 11, 2008
Teva Announces Brussels Court Decision To Revoke MSD's European Patent On Fosamax®
|
|
Jerusalem, Israel, April 11, 2008
Teva Receives Court Ruling Awarding Exclusivity For Generic Risperdal®
|
|
Jerusalem, Israel, April 10, 2008
Copaxone® Significantly Reduced Annual Relapse Rates And Stabilized Disease Progression In Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment
|
|
Jerusalem, Israel, March 31, 2008
Teva Provides Update On Generic Prevacid® Litigation
|
|
Jerusalem, Israel and Exeter, NH, March 31, 2008
Teva to Acquire Bentley Pharmaceuticals
|
|
Jerusalem, Israel, March 28, 2008
Teva Provides Update On Generic Aricept® Litigation
|
|
Jerusalem, Israel, March 25, 2008
Teva Reports 2007 Financials in XBRL Standard
|
|
Jerusalem, Israel, March 17, 2008
Teva to Present at the Lehman Brothers 11th Annual Global Healthcare Conference and at the Cowen and Company 28th Annual Healthcare Conference
|
|
Jerusalem, Israel, March 13, 2008
Teva Provides Update On Glatiramer Acetate 40mg For Amyotrophic Lateral Sclerosis (ALS)
|
|
Jerusalem, Israel, March 12, 2008
Teva To Present At The Bear Stearns 10th Annual London Healthcare Conference
|
|
Jerusalem, Israel, March 5, 2008
Teva Provides Update On Generic Risperdal®
|
|
Jerusalem, Israel, February 29, 2008
Teva Provides Update On Generic Actonel® Litigation
|
|
Jerusalem, Israel, February 28, 2008
Teva Announces Approval Of Generic Camptosar®
|
|
Jerusalem, Israel, February 25, 2008
Teva Announces Two Court Decisions to Revoke MSD's European Patent on Generic Fosamax®
|
|
Jerusalem, Israel, February 21, 2008
Teva's Developed G-CSF is the First Biosimilar to Receive a Positive Opinion from European Union Regulators
|
|
Jerusalem, Israel, February 21, 2008
Teva Presents Growth Strategy At Investor Day
Company Provides Long Term Strategic Goals
Teva Announces Closing Of Cogenesys Acquisition
|
|
Jerusalem, Israel, February 19, 2008
Teva Invites Public To Listen To Investor Day Webcast
|
|
Jerusalem, Israel, February 12, 2008
Teva Provides 2008 And 2009 Financial Outlook
|
|
Jerusalem, Israel, February 12, 2008
Teva Reports Fourth Quarter And Full Year 2007 Results
|
|
Jerusalem, Israel, February 6, 2008
Teva Announces Approval of Generic Fosamax® Tablets
|
|
Jerusalem, Israel, February 1, 2008
Teva Provides Update On Generic Protonix®
|
|
Jerusalem, Israel, January 31, 2008
Teva Announces Tentative Approval Of Generic Flomax® Capsules
|
|
Jerusalem, Israel, January 30, 2008
Teva Announces Wyeth Voids Standstill Agreement On Generic Protonix®
|
|
Jerusalem, Israel, January 29, 2008
Teva To Present At The 2008 Wachovia Healthcare Conference
|
|
Jerusalem, Israel, January 29, 2008
Teva To Report Fourth Quarter And Full Year 2007 Financial Results On February 12, 2008
|
|
Jerusalem, Israel, January 23, 2008
Teva Announces Tentative Approval Of Generic Prevacid® Delayed-Release Capsules
|
|
Jerusalem, Israel, January 22, 2008
Teva Announces Extension To Standstill Agreement On Generic Protonix®
|
|
Jerusalem, Israel, January 22, 2008
Teva to Acquire CoGenesys
Acquisition Will Bolster Teva's Biotechnology Capabilities
|
|
Jerusalem, Israel, January 17, 2008
Teva Announces Approval Of Pravastatin Sodium Tablets, 80 Mg
|
|
North Wales, Pa. and Atlanta, January 16, 2008
Teva Specialty Pharmaceuticals And UCB Announce U.S. Respiratory Collaboration Agreement
|
|
Jerusalem, Israel, January 14, 2008
Teva Announces Tentative Approval Of Generic Aricept® Tablets
|
|
Jerusalem, Israel, January 14, 2008
Teva to Explore Strategic Alternatives for its Animal Health Business
|
|
Jerusalem, Israel, January 10, 2008
Teva Announces Departure Of North American CEO ,
William S. Marth To Become Ceo Of Teva North America
|
|
Jerusalem, Israel, January 3, 2008
Teva to Present at the Morgan Stanley Pharmaceutical CEO's Unplugged Conference and at the 26th Annual JPMorgan Healthcare Conference
|
|
Jerusalem, Israel, January 3, 2008
Teva Announces Approval Of Generic Kytril® Injection And Tablets
|
|
Jerusalem, Israel, January 2, 2008
Teva Announces Approval Of Generic Duoneb®
|
